New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
16:53 EDTQUREuniQure acquires InoCard in cash, stock
uniQure announced the acquisition of InoCard GmbH, an innovative, early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease. InoCard founders Patrick Most and Hugo Katus will join uniQure as managing director of uniQure in Germany and chairman of the scientific advisory board, for cardiovascular diseases, respectively. Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3M, 1.5M in cash and 1.5M in uniQure stock, and certain success-based milestones and royalties.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
13:44 EDTQURE to host investor day
Subscribe for More Information
October 5, 2015
10:19 EDTQURESpark trial success a positive for gene therapy sector, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer said he views the news that Spark Therapeutics (ONCE) "highly anticipated" SPK-RPE65 Phase 3 gene therapy study for congenital blindness met its primary endpoint as a positive for the ophthalmology gene therapy field as well as the broader gene therapy sector. Schimmer added that Applied Genetic Technologies' (AGTC) early clinical data in the second half of this year will be a further test of the ophthalmology gene therapy platform. The analyst noted that other companies with gene therapy programs include Avalanche (AAVL), Biogen (BIIB), bluebird bio (BLUE), BioMarin (BMRN), Cellectis (CLLS), Medgenics (MDGN), uniQure (QURE), Pfizer (PFE), Regeneron (REGN) and Sangamo (SGMO).
September 28, 2015
09:19 EDTQUREuniQure weakness creates buying opportunity, says Roth Capital
Noting that uniQure has sold off amid worries about the high cost of its gene therapy, Roth Capital says that uniQure's gene therapy is less costly than the current lifetime treatment regimen for hemophiliacs. The firm thinks that the sell-off in the stock has created a buying opportunity for long-term investors. It keeps a $38 price target and Buy rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use